Search results
FDA panel rejects MDMA-assisted therapies for PTSD despite high hopes from veterans
Fox News via Yahoo News· 2 days agoAn FDA panel rejected MDMA-based treatments for PTSD often used with veterans. One advocate shared...
The Supreme Court Sides With the FDA on the Abortion Pill—for Now
The Nation· 2 days agoWhen the US Supreme Court held Thursday that the plaintiffs in Alliance for Hippocratic Medicine v. ...
Why FDA Panel Rejected MDMA Therapy—And What’s Next For Psychedelic Medicine
Forbes· 2 days agoHigh hopes that psychedelic medicines were finally on the pathway to regulation were dashed last...
Vertex says Casgevy benefit extends to nearly five years in sickle cell disease
Clinical Trials Arena via Yahoo Finance· 1 day agoThe US pharma company is due to present the data from its CLIMB trials at the EHA Congress....
The pros and cons of pooling supplies for clinical trials
Clinical Trials Arena via Yahoo Finance· 3 days agoHow do regulators feel about pooled supplies? There are regulatory concerns to navigate when pooling...
Concern Grows Over Bird Flu Outbreak in Dairy Cows
The Dispatch via Yahoo News· 1 day agoStill, Reuters reported that a handful of cows in South Dakota, Michigan, Texas, Ohio, and Colorado have died or were killed by farmers when they didn’t...
Health Care Week In Review: House Held Oversight Hearing on the 340B Program and HHS Expanded...
JD Supra· 6 days agoBelow is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance;...
Semtech Target of Unusually Large Options Trading (NASDAQ:SMTC)
ETF DAILY NEWS· 7 days agoSemtech Co. (NASDAQ:SMTC – Get Free Report) was the recipient of unusually large options trading activity on Friday. In other Semtech news, CFO Mark Lin bought 1,000 shares of the firm’s stock ...
Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy...
Morningstar· 4 days agoThe Portnoy Law Firm advises Akero Therapeutics, Inc. ("Akero" or the “Company”) (NASDAQ: AKRO) investors that a class action has been filed on behalf of investors. Akero investors that lost ...
Alzheimer's drug that can slow disease gets backing from FDA advisers
McComb Enterprise-Journal· 5 days agoA sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers ...